NanoClear Nanobots Patrol Bloodvessels to Dissolve Arterial Plaque

Microscopic Cleaners in Your Bloodvessels — Nanobots Take on Arterial Plaque

Atherosclerosis is the world's number one killer, claiming roughly 18 million lives each year. Current treatments are either pharmaceutical (statins slow plaque growth but cannot reverse it) or surgical (stents and bypass grafts carry trauma and a risk of restenosis).

VascularRobotics' NanoClear offers an entirely new paradigm: nanobots that physically remove plaque from inside bloodvessels. Data published on April 30 demonstrated that NanoClear successfully cleared moderate plaque from coronary arteries in a pig model.

Each NanoClear unit is a spherical robot about 200 nanometers in diameter. Its outer coating carries plaque-degrading enzymes (capable of breaking down cholesterol crystals and fibrin), while its core contains magnetic nanoparticles used for external magnetic-field navigation. After injection into the bloodstream, the nanobots cruise through vessels using a combination of blood flow and externally applied magnetic fields.

"The design philosophy behind NanoClear is 'don't destroy, just clean,'" explained VascularRobotics' chief scientist Dr. Sarah Kim. "The enzymes act only on plaque components and leave healthy vessel-wall tissue unharmed."

In the experiment, 20 pigs with artificially induced moderate coronary plaque received NanoClear via catheter injection. Guided by magnetic fields, the nanobots cruised the target area for four hours. Post-examination showed a 35% average reduction in plaque volume with no detectable vessel-wall damage.

The experiment also revealed limitations. NanoClear proved far less effective against heavily calcified (hard) plaque than against soft plaque. Additionally, the in-vivo metabolic pathway of the nanobots requires more thorough safety study.

VascularRobotics plans to launch a Phase I human clinical trial by the end of 2031. If successful, NanoClear could reach clinical use around 2034.